Niagen Bioscience Sponsors Inaugural NAD for Health Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy NAGE?
Source: Newsfilter
- Event Timing and Location: Niagen Bioscience is the headlining sponsor of the inaugural NAD for Health conference, taking place from March 23-25, 2026, at the Royal Danish Academy of Sciences in Copenhagen, aimed at fostering evidence-based dialogue in NAD+ science and accelerating clinical translation, expected to attract top experts globally.
- Scientific Themes and Objectives: The conference will focus on NAD metabolism and its implications for human health, covering topics such as rare diseases, healthspan extension, and neurodegenerative diseases, with the goal of identifying knowledge gaps and accelerating clinical translation through interdisciplinary dialogue.
- Participants and Program Structure: The meeting will bring together researchers, clinicians, and industry partners from renowned institutions, featuring thematic sessions, a panel discussion, and a dedicated poster session for early-career researchers, facilitating the sharing of new insights.
- Registration and Participation Limitations: Due to limited space, registration is required, and attendance is subject to confirmation, highlighting the high demand for the conference and its significance in the NAD research field, further enhancing Niagen Bioscience's industry influence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.110
Low
12.00
Averages
16.33
High
23.00
Current: 5.110
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Niagen® Expands into Skincare Market with Innovative Product Launch
- Skincare Innovation Lab: Niagen Bioscience has launched the Niagen® Skincare Innovation Lab, aiming to translate its leadership in NAD+ science into skincare innovation, marking the company's entry into the $122.11 billion global skincare market.
- First Product Launch: The inaugural product, Niagen NanoCloud, utilizes a sealed, waterless format to ensure the stability of NAD+ ingredients until use, expected to significantly enhance skincare efficacy and meet consumer demand for effective products.
- Significant Market Potential: Market research indicates that the global anti-aging cosmetics market is projected to reach $106.98 billion by 2035, and Niagen's entry positions it well within the rapidly growing skincare sector, driving future product development.
- Positive Consumer Feedback: A study involving 37 female participants found that consistent use of Niagen NanoCloud resulted in visible skin improvements within two weeks, indicating the product's effectiveness in enhancing skin texture and hydration, thereby strengthening the brand's competitive position in the market.
See More
Niagen Bioscience Reports Q4 and Full-Year 2025 Financial Results
- Financial Performance Overview: Niagen Bioscience reported a Q4 net income of $4.1 million, or $0.05 per share, down from $7.2 million and $0.09 per share in the previous year, indicating challenges in profitability.
- Sales Growth Analysis: Total net sales for Q4 2025 reached $33.84 million, a 16% increase, while full-year sales grew by 30% to $129.4 million, reflecting strong market demand and operational effectiveness.
- Cash Flow Status: As of December 31, 2025, the company had cash and cash equivalents totaling $64.8 million, up from $44.7 million the previous year, enhancing financial stability and capacity for future investments.
- Future Outlook: For 2026, Niagen anticipates a net sales growth of 10-15%, primarily driven by e-commerce and new strategic partnerships, indicating a proactive approach to market expansion and product innovation.
See More
Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance
- Strong Financials: Veeva Systems reported Q4 revenue of $836 million, a 16% year-over-year increase, surpassing the market expectation of $810.6 million, indicating robust growth potential in the life sciences sector.
- Earnings Beat: The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.93, reflecting ongoing improvements in profitability and boosting investor confidence.
- Stock Surge: Veeva Systems shares jumped 11.3% in pre-market trading to $209.81, indicating a positive market reaction to its financial performance and future outlook.
- Optimistic Guidance: The company raised its FY27 guidance above market expectations, further solidifying its leadership position in the industry and laying a strong foundation for future growth.
See More
Niagen Bioscience Shares Surge 18.41% After Strong Financials
- Strong Financial Performance: Niagen Bioscience reported a full-year net sales of $129.4 million for 2025, marking a 30% year-over-year increase and reaching the upper end of its forecast, while net income surged to $17.7 million, nearly doubling last year's $8.6 million, indicating robust market demand and profitability.
- Solid Cash Position: The company holds $64.8 million in cash with zero debt, providing a strong financial foundation for future expansions and acquisitions, thereby enhancing investor confidence in its long-term growth potential.
- Acquisition Potential: CEO Rob Fried stated that the company is actively evaluating acquisition targets, and while no specific deals have been finalized yet, this strategic intent could provide new momentum for future growth and enhance market competitiveness.
- Conservative 2026 Outlook: Management projects revenue of $145 million for 2026, representing approximately 15% growth; although the company has historically maintained a conservative approach to projections, this growth expectation still reflects confidence in the market and a proactive stance towards business expansion.
See More
Niagen Bioscience Q4 2025 Earnings Highlights
- Significant Revenue Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with full-year revenue reaching $129.4 million, representing a 30% growth, indicating strong market performance and sustained growth potential.
- Net Income Improvement: The net income for Q4 was $4.1 million, translating to $0.05 per share, while the annual net income reached $17.4 million, a 102% increase from 2024, reflecting the company's success in operational efficiency and cost control.
- New Product Strategy: The company plans to launch Niagen Plus at-home injection kits in the first half of 2026 and aims to partner with other telehealth providers, showcasing its proactive approach in innovative products and services.
- Legal Challenges and Market Outlook: Niagen Bioscience has initiated litigation in federal court in Washington, D.C. against the FDA's reversal on NMN's supplement status, with management expressing confidence in the case, while projecting revenue growth of 10% to 15% for 2026, reflecting a cautious stance towards competitive and regulatory risks.
See More
U.S. and Ecuador Jointly Target Drug Traffickers
- Joint Military Operation: The U.S. and Ecuador conducted a joint military operation on Tuesday targeting criminal gangs designated as foreign terrorist organizations, such as Los Choneros and Los Lobos, marking a new phase in Washington's campaign against drug trafficking in Latin America.
- Deepening Strategic Cooperation: Ecuadorian President Noboa stated that the country is entering a new phase in its fight against organized crime, emphasizing the continuation of joint missions with international partners to aggressively tackle narcotrafficking and illegal mining threats.
- Enhanced Technical Support: U.S. support includes funding for surveillance technology and drones, as well as the temporary deployment of Air Force personnel to Ecuador's Manta air base to assist with anti-drug missions, highlighting the importance of Ecuador as a key partner in this effort.
- Response to Rising Violence: Despite capturing two major gang leaders in the past year, violence continues to escalate in Ecuador, prompting the government to implement aggressive security measures, including troop deployments and expanded emergency powers, to address the growing drug-related violence.
See More
Niagen® Expands into Skincare Market with Innovative Product Launch
- Skincare Innovation Lab: Niagen Bioscience has launched the Niagen® Skincare Innovation Lab, aiming to translate its leadership in NAD+ science into skincare innovation, marking the company's entry into the $122.11 billion global skincare market.
- First Product Launch: The inaugural product, Niagen NanoCloud, utilizes a sealed, waterless format to ensure the stability of NAD+ ingredients until use, expected to significantly enhance skincare efficacy and meet consumer demand for effective products.
- Significant Market Potential: Market research indicates that the global anti-aging cosmetics market is projected to reach $106.98 billion by 2035, and Niagen's entry positions it well within the rapidly growing skincare sector, driving future product development.
- Positive Consumer Feedback: A study involving 37 female participants found that consistent use of Niagen NanoCloud resulted in visible skin improvements within two weeks, indicating the product's effectiveness in enhancing skin texture and hydration, thereby strengthening the brand's competitive position in the market.
See More
Niagen Bioscience Reports Q4 and Full-Year 2025 Financial Results
- Financial Performance Overview: Niagen Bioscience reported a Q4 net income of $4.1 million, or $0.05 per share, down from $7.2 million and $0.09 per share in the previous year, indicating challenges in profitability.
- Sales Growth Analysis: Total net sales for Q4 2025 reached $33.84 million, a 16% increase, while full-year sales grew by 30% to $129.4 million, reflecting strong market demand and operational effectiveness.
- Cash Flow Status: As of December 31, 2025, the company had cash and cash equivalents totaling $64.8 million, up from $44.7 million the previous year, enhancing financial stability and capacity for future investments.
- Future Outlook: For 2026, Niagen anticipates a net sales growth of 10-15%, primarily driven by e-commerce and new strategic partnerships, indicating a proactive approach to market expansion and product innovation.
See More
Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance
- Strong Financials: Veeva Systems reported Q4 revenue of $836 million, a 16% year-over-year increase, surpassing the market expectation of $810.6 million, indicating robust growth potential in the life sciences sector.
- Earnings Beat: The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.93, reflecting ongoing improvements in profitability and boosting investor confidence.
- Stock Surge: Veeva Systems shares jumped 11.3% in pre-market trading to $209.81, indicating a positive market reaction to its financial performance and future outlook.
- Optimistic Guidance: The company raised its FY27 guidance above market expectations, further solidifying its leadership position in the industry and laying a strong foundation for future growth.
See More
Niagen Bioscience Shares Surge 18.41% After Strong Financials
- Strong Financial Performance: Niagen Bioscience reported a full-year net sales of $129.4 million for 2025, marking a 30% year-over-year increase and reaching the upper end of its forecast, while net income surged to $17.7 million, nearly doubling last year's $8.6 million, indicating robust market demand and profitability.
- Solid Cash Position: The company holds $64.8 million in cash with zero debt, providing a strong financial foundation for future expansions and acquisitions, thereby enhancing investor confidence in its long-term growth potential.
- Acquisition Potential: CEO Rob Fried stated that the company is actively evaluating acquisition targets, and while no specific deals have been finalized yet, this strategic intent could provide new momentum for future growth and enhance market competitiveness.
- Conservative 2026 Outlook: Management projects revenue of $145 million for 2026, representing approximately 15% growth; although the company has historically maintained a conservative approach to projections, this growth expectation still reflects confidence in the market and a proactive stance towards business expansion.
See More
Niagen Bioscience Q4 2025 Earnings Highlights
- Significant Revenue Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with full-year revenue reaching $129.4 million, representing a 30% growth, indicating strong market performance and sustained growth potential.
- Net Income Improvement: The net income for Q4 was $4.1 million, translating to $0.05 per share, while the annual net income reached $17.4 million, a 102% increase from 2024, reflecting the company's success in operational efficiency and cost control.
- New Product Strategy: The company plans to launch Niagen Plus at-home injection kits in the first half of 2026 and aims to partner with other telehealth providers, showcasing its proactive approach in innovative products and services.
- Legal Challenges and Market Outlook: Niagen Bioscience has initiated litigation in federal court in Washington, D.C. against the FDA's reversal on NMN's supplement status, with management expressing confidence in the case, while projecting revenue growth of 10% to 15% for 2026, reflecting a cautious stance towards competitive and regulatory risks.
See More
U.S. and Ecuador Jointly Target Drug Traffickers
- Joint Military Operation: The U.S. and Ecuador conducted a joint military operation on Tuesday targeting criminal gangs designated as foreign terrorist organizations, such as Los Choneros and Los Lobos, marking a new phase in Washington's campaign against drug trafficking in Latin America.
- Deepening Strategic Cooperation: Ecuadorian President Noboa stated that the country is entering a new phase in its fight against organized crime, emphasizing the continuation of joint missions with international partners to aggressively tackle narcotrafficking and illegal mining threats.
- Enhanced Technical Support: U.S. support includes funding for surveillance technology and drones, as well as the temporary deployment of Air Force personnel to Ecuador's Manta air base to assist with anti-drug missions, highlighting the importance of Ecuador as a key partner in this effort.
- Response to Rising Violence: Despite capturing two major gang leaders in the past year, violence continues to escalate in Ecuador, prompting the government to implement aggressive security measures, including troop deployments and expanded emergency powers, to address the growing drug-related violence.
See More
